NVTA

Invitae Corporation (NVTA) | Rumor.io

Invitae

NVTA

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)4%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about NVTA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Nov 18

NVTA is expected to run up.
No additional market-relevant information is available.
No further comments on NVTA are provided.

Generated by AI

Sentiment

Of the messages about NVTA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% -3.78	18.81% -56.75
Bearish	—	—	100% +3.78	81.19% +56.75

Bullish· Sep 25

NVTA is poised for a significant price increase.
Market conditions are favorable for NVTA to reach new highs.
Investor sentiment is optimistic, with many expecting a strong performance from the company.

Bearish· Feb 8

$NVTA's stock has dropped significantly, from $1.2 to $0.3, over the last 6 months, indicating warning signs that were ignored by ARK and Invitae management.
Invitae's stock has de-listed from the NYSE and moved to the OTC market, which is considered a "cesspool" with low liquidity and high potential for manipulation.
Cathie Wood's investment in $NVTA has lost significant value, with 32.5M shares sold at $40 now worth $0.08, highlighting the risks of following a fund manager's decisions.

Generated by AI

Topics

Of the messages about NVTA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Earnings· Feb 20

Invitae Corporation (NVTA) reported a Q4 loss of $0.79 per share, missing revenue estimates by $0.03 EPS.
The company's revenue rose 46.0% year/year to $66.3 million, but fell short of the $66.62 million S&P Capital Consensus.
NVTA's stock price was down 13.4% in the premarket following the earnings miss, with the company's CEO discussing the Q4 2019 results on an earnings call.

Analysts· Feb 18

Ladenburg Thalmann analyst Jeffrey Cohen upgraded Invitae to Buy from Neutral with a price target of $58, citing growth potential and cost controls.
SVB Leerink increased Invitae's price target to $65.00, citing the company's growth potential.
Ladenburg Thalmann upgraded Invitae to Buy from Neutral, raising its price target from $46.50 to $58 per share, driven by the company's better-than-expected Q4 sales results.

Announcements· Oct 8

Invitae Corporation (NVTA) has not been mentioned in the provided post, which is primarily about Mainz Biomed.
No information about Invitae Corporation (NVTA) is available from the given post.
The post discusses Mainz Biomed's focus on non-invasive cancer screening and its potential to capture the growing diagnostic market.

Technical Analysis· Sep 11

NVTA held support on Friday and may break out early in the week.
A possible breakout is being considered in a 15-minute timeframe.
An ascending pattern is being observed in the stock.

Generated by AI

Community

Of the messages about NVTA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	26.32%	75.19%
Newcomers	100%	100%	73.68%	24.81%

Regulars· Feb 15

Invitae Corporation ($NVTA) is reportedly preparing for a potential Chapter 11 bankruptcy or receivership, with a common share wipeout appearing likely.
The outcome of Invitae's bankruptcy proceedings will determine whether the company's shares are canceled, with some speculating that a reemergence from Chapter 11 could preserve the shares.
Invitae's business model and profit potential are uncertain, with some investors questioning the company's ability to generate significant revenue from its sequencing technology.

Newcomers· Oct 31

Mainz Biomed's ColoAlert is being featured at top medical conferences, indicating a big validation ahead.
Mainz Biomed is focusing on health, making it a potential top stock pick for diagnostics this year.
Invitae Corporation ($NVTA) is mentioned alongside Mainz Biomed, suggesting a possible comparison or connection between the two companies.

Generated by AI

Also Discussed

Investors talking about NVTA also mention

#	Name	Attention
1	Pacific Biosciences of California, Inc. Common StockPACB	0%0
2	CRISPR Therapeutics AGCRSP	0%0
3	Illumina Inc.ILMN	0%+0
4	Twist Bioscience CorporationTWST	0%-0.02
5	TWOU - 2U, Inc.	——
6	10x Genomics Inc. Class A Common StockTXG	0%-0.02
7	Intellia Therapeutics, Inc.NTLA	0%+0
8	NSTG - NanoString Technologies, Inc.	——
9	Teladoc Health Inc.TDOC	0%+0
10	EXAS - Exact Sciences Corporation	——

Invitae Corporation

Location

Social

What share of all stock conversation is about NVTA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Nov 18

NVTA is expected to run up.
No additional market-relevant information is available.
No further comments on NVTA are provided.

Generated by AI

Sentiment

Of the messages about NVTA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% -3.78	18.81% -56.75
Bearish	—	—	100% +3.78	81.19% +56.75

Bullish· Sep 25

NVTA is poised for a significant price increase.
Market conditions are favorable for NVTA to reach new highs.
Investor sentiment is optimistic, with many expecting a strong performance from the company.

Bearish· Feb 8

$NVTA's stock has dropped significantly, from $1.2 to $0.3, over the last 6 months, indicating warning signs that were ignored by ARK and Invitae management.
Invitae's stock has de-listed from the NYSE and moved to the OTC market, which is considered a "cesspool" with low liquidity and high potential for manipulation.
Cathie Wood's investment in $NVTA has lost significant value, with 32.5M shares sold at $40 now worth $0.08, highlighting the risks of following a fund manager's decisions.

Generated by AI

Topics

Of the messages about NVTA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Earnings· Feb 20

Invitae Corporation (NVTA) reported a Q4 loss of $0.79 per share, missing revenue estimates by $0.03 EPS.
The company's revenue rose 46.0% year/year to $66.3 million, but fell short of the $66.62 million S&P Capital Consensus.
NVTA's stock price was down 13.4% in the premarket following the earnings miss, with the company's CEO discussing the Q4 2019 results on an earnings call.

Analysts· Feb 18

Ladenburg Thalmann analyst Jeffrey Cohen upgraded Invitae to Buy from Neutral with a price target of $58, citing growth potential and cost controls.
SVB Leerink increased Invitae's price target to $65.00, citing the company's growth potential.
Ladenburg Thalmann upgraded Invitae to Buy from Neutral, raising its price target from $46.50 to $58 per share, driven by the company's better-than-expected Q4 sales results.

Announcements· Oct 8

Invitae Corporation (NVTA) has not been mentioned in the provided post, which is primarily about Mainz Biomed.
No information about Invitae Corporation (NVTA) is available from the given post.
The post discusses Mainz Biomed's focus on non-invasive cancer screening and its potential to capture the growing diagnostic market.

Technical Analysis· Sep 11

NVTA held support on Friday and may break out early in the week.
A possible breakout is being considered in a 15-minute timeframe.
An ascending pattern is being observed in the stock.

Generated by AI

Community

Of the messages about NVTA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	26.32%	75.19%
Newcomers	100%	100%	73.68%	24.81%

Regulars· Feb 15

Invitae Corporation ($NVTA) is reportedly preparing for a potential Chapter 11 bankruptcy or receivership, with a common share wipeout appearing likely.
The outcome of Invitae's bankruptcy proceedings will determine whether the company's shares are canceled, with some speculating that a reemergence from Chapter 11 could preserve the shares.
Invitae's business model and profit potential are uncertain, with some investors questioning the company's ability to generate significant revenue from its sequencing technology.

Newcomers· Oct 31

Mainz Biomed's ColoAlert is being featured at top medical conferences, indicating a big validation ahead.
Mainz Biomed is focusing on health, making it a potential top stock pick for diagnostics this year.
Invitae Corporation ($NVTA) is mentioned alongside Mainz Biomed, suggesting a possible comparison or connection between the two companies.

Generated by AI

Invitae

Social

Nov 18

Sentiment

Bullish· Sep 25

Bearish· Feb 8

Topics

Earnings· Feb 20

Analysts· Feb 18

Announcements· Oct 8

Technical Analysis· Sep 11

Community

Regulars· Feb 15

Newcomers· Oct 31

Also Discussed

Invitae Corporation

Company Information

Location

Also Discussed

Social

Nov 18

Sentiment

Bullish· Sep 25

Bearish· Feb 8

Topics

Earnings· Feb 20

Analysts· Feb 18

Announcements· Oct 8

Technical Analysis· Sep 11

Community

Regulars· Feb 15

Newcomers· Oct 31